Galmed Pharmaceuticals (GLMD) Debt to Equity (2013 - 2016)
Galmed Pharmaceuticals (GLMD) recorded quarterly Debt to Equity of $0.07 in Q4 2016, up 132.76% quarter-over-quarter from -$0.22 in Q4 2013.
Galmed Pharmaceuticals (GLMD) Debt to Equity (2013 - 2016) Analysis & Trends
Galmed Pharmaceuticals' Debt to Equity history runs 2 years deep, the most recent figure standing at $0.07 for Q4 2016.
- In Q4 2016, Debt to Equity changed N/A year-over-year to $0.07; the TTM figure through Dec 2016 stood at $0.07 (changed N/A YoY), while the FY2016 annual figure was $0.07, changed N/A from the prior year.
- Debt to Equity was $0.07 for Q4 2016 at Galmed Pharmaceuticals, up from -$0.22 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.07 in Q4 2016 to a low of -$0.22 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 0.07 |
| Dec 31, 2013 | -0.22 |